{"title":"恩格列净治疗保留射血分数的心力衰竭患者——系统评价","authors":"","doi":"10.33140/coa.08.01.02","DOIUrl":null,"url":null,"abstract":"Objective: The goal of this systematic review is to determine the effectiveness of empagliflozin in managing patients with heart failure with preserved ejection fraction (HFpEF) as compared with a placebo. Methods: Web of Science, Cochrane, PubMed, and Scopus databases were searched for articles from 2000 to November 2022. Reference lists of articles were manually screened. Trials that recruited patients with HFpEF and reported the effects of empagliflozin were included. Endnote X9 software was used for study screening process. Results: 14 papers out of 1235 found were selected for full-text reviews. The systematic review included nine papers that were all randomized controlled trials. According to the findings of individual trials, empagliflozin is more effective and has a statistically insignificant safety advantage over a placebo. Conclusion: Empagliflozin treatment for HFpEF patients appears to be both safe and efficient when compared to a placebo, according to data of moderate quality","PeriodicalId":93027,"journal":{"name":"Journal of integrative cardiology open access","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Empagliflozin Treatment for Patients with Heart Failure with Preserved Ejection Fraction-A Systematic Review\",\"authors\":\"\",\"doi\":\"10.33140/coa.08.01.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The goal of this systematic review is to determine the effectiveness of empagliflozin in managing patients with heart failure with preserved ejection fraction (HFpEF) as compared with a placebo. Methods: Web of Science, Cochrane, PubMed, and Scopus databases were searched for articles from 2000 to November 2022. Reference lists of articles were manually screened. Trials that recruited patients with HFpEF and reported the effects of empagliflozin were included. Endnote X9 software was used for study screening process. Results: 14 papers out of 1235 found were selected for full-text reviews. The systematic review included nine papers that were all randomized controlled trials. According to the findings of individual trials, empagliflozin is more effective and has a statistically insignificant safety advantage over a placebo. Conclusion: Empagliflozin treatment for HFpEF patients appears to be both safe and efficient when compared to a placebo, according to data of moderate quality\",\"PeriodicalId\":93027,\"journal\":{\"name\":\"Journal of integrative cardiology open access\",\"volume\":\"58 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of integrative cardiology open access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/coa.08.01.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of integrative cardiology open access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/coa.08.01.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:本系统评价的目的是确定与安慰剂相比，恩格列净治疗保留射血分数(HFpEF)的心力衰竭患者的有效性。方法:检索Web of Science、Cochrane、PubMed和Scopus数据库2000年至2022年11月的文章。参考文献列表是手工筛选的。纳入了招募HFpEF患者并报告了恩格列净效果的试验。使用Endnote X9软件进行研究筛选过程。结果:1235篇论文中有14篇入选全文综述。系统综述包括9篇论文，均为随机对照试验。根据个别试验的结果，恩格列净比安慰剂更有效，而且在统计学上没有明显的安全性优势。结论:根据中等质量的数据，与安慰剂相比，恩格列净治疗HFpEF患者似乎既安全又有效
Empagliflozin Treatment for Patients with Heart Failure with Preserved Ejection Fraction-A Systematic Review
Objective: The goal of this systematic review is to determine the effectiveness of empagliflozin in managing patients with heart failure with preserved ejection fraction (HFpEF) as compared with a placebo. Methods: Web of Science, Cochrane, PubMed, and Scopus databases were searched for articles from 2000 to November 2022. Reference lists of articles were manually screened. Trials that recruited patients with HFpEF and reported the effects of empagliflozin were included. Endnote X9 software was used for study screening process. Results: 14 papers out of 1235 found were selected for full-text reviews. The systematic review included nine papers that were all randomized controlled trials. According to the findings of individual trials, empagliflozin is more effective and has a statistically insignificant safety advantage over a placebo. Conclusion: Empagliflozin treatment for HFpEF patients appears to be both safe and efficient when compared to a placebo, according to data of moderate quality
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
